| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 02 Nov 2026 |
Form 4: LaChapelle Robin, Chief Operating Officer
Received 40,693 shares by exercise or conversion ($185K) |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 13 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 08 Oct 2026 | SCHEDULE 13D/A |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 22 Jun 2026 |
Form 4: Parsey Merdad, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Peterson Kristine, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Hohneker John, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Nolet Chris, Director
Granted 13,562 Non-Qualified Stock Option (right to buy) |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share,... |
| 11 May 2026 |
8-K: Other Events
We have acted as counsel to ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), with respect to certain matters in connection with the Automatic Shelf Registration Statement on Form S-3ASR (File No. 333-284661) (the “Regist... |
| 11 May 2026 | 424B5 |
Loading...